mRNAutilus: Multi-Objective-Guided Discrete Generation of mRNA with Optimized Therapeutic Properties

arXiv:2605.31296v1 Announce Type: cross Abstract: Therapeutic mRNA design requires coordinating multiple interacting sequence features across the full transcript, where codon usage, untranslated regions (UTRs), and their coupling jointly determine stability, translation efficiency, and protein expression. Here, we present mRNA generation via unrolled trajectories and informed latent updates (mRNAutilus), a framework for simultaneous codon optimization and de novo UTR design directly from sequence. mRNAutilus combines a masked discrete diffusion model trained on millions of full-length mRNAs wi
The convergence of advanced AI models with biological engineering is enabling sophisticated design of therapeutic molecules at an accelerated pace, moving beyond traditional trial-and-error methods.
This development represents a significant step towards more effective and precisely engineered mRNA therapeutics, potentially revolutionizing vaccine development and disease treatment.
The ability to simultaneously optimize multiple mRNA sequence features using AI will lead to more stable, potent, and efficient mRNA drugs, reducing development time and improving patient outcomes.
- · Biotech companies
- · Pharmaceutical companies
- · Patients
- · AI-driven drug discovery platforms
- · Traditional drug discovery methods
- · Companies without AI integration
Further acceleration in the development of new mRNA-based therapies for a wider range of diseases.
Increased investment and competition in the synthetic biology and AI-driven drug design sectors, leading to a boom in related research and product development.
Ethical and regulatory discussions around the rapid design and deployment of highly optimized biological agents, prompting new frameworks for oversight.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG